Quantcast

BHV Pharmaceuticals and Kissei Pharmaceutical Co. Ltd. Sign Exclusive Worldwide License Agreement for Late-Stage Development Product Remogliflozin Etabonate

January 9, 2011

BHV Pharmaceuticals, a clinical-stage drug development company, announced today it has entered into a license agreement with Kissei Pharmaceutical Co. Ltd. for exclusive rights to develop and commercialize Remogliflozin Etabonate, a novel, highly selective SGLT2 inhibitor. The agreement provides BHV exclusive global rights excluding Japan, Korea, and Taiwan. Commercialization in China will be shared between Kissei and BHV. Remogliflozin etabonate is a Phase IIb compound in development for the treatment of Type II diabetes.

Research Triangle Park, NC (PRWEB) January 7, 2011

BHV Pharmaceuticals, a clinical-stage drug development company, announced today it has entered into a license agreement with Kissei Pharmaceutical Co. Ltd. for exclusive rights to develop and commercialize Remogliflozin Etabonate, a novel, highly selective SGLT2 inhibitor. The agreement provides BHV exclusive global rights excluding Japan, Korea, and Taiwan. Commercialization in China will be shared between Kissei and BHV. Remogliflozin etabonate is a Phase IIb compound in development for the treatment of Type II diabetes.

In the agreement, Kissei is eligible to receive additional payments if certain development and regulatory milestones are achieved. Kissei will receive royalties on net sales.

“Kissei has done an outstanding job developing Remogliflozin Etabonate as evidenced by the efficacy, safety and tolerability profiles demonstrated in the data collected to date. We are excited to have the opportunity to develop a potentially class leading treatment for diabetics” said William Wilkison, Chief Scientific Officer, BHV. James Green, BHV Chief Business Officer added, “This is a significant milestone in the history of BHV and we look forward to working with Kissei to continue the development of Remogliflozin Etabonate. SGLT2 inhibitors are an exciting new class of treatment for diabetes and our focus will be to leverage the unique characteristics of the molecule to provide diabetics a greater positive outcome than other SGLT2 inhibitors currently in development.”

About Remogliflozin Etabonate

Remogliflozin is a new chemical entity (NCE) that selectively inhibits the sodium glucose transporter 2. This compound has been assessed for efficacy, tolerability and safety in multiple clinical trials, including two Phase IIb type II diabetes studies. Other studies that have been completed in the development of this compound include standard toxicology, pharmacology, safety and food and drug interaction studies.

About BHV Pharmaceuticals

BHV, a Research Triangle Park-based clinical-stage drug development company, is focused on developing therapeutics for the treatment of metabolic diseases such as diabetes and obesity. http://www.bhvpharma.com.

About Kissei Pharmaceuticals

Kissei Pharmaceutical Co., Ltd. was founded in 1946 and has grown into one of Japan’s leading pharmaceutical companies. Kissei’s management vision is to be an R&D-oriented pharmaceutical company that contributes to the health of people around the world through developing and commercializing innovative drugs. Kissei is actively pursuing collaborations with many companies to strengthen its R&D pipeline, and also promoting global expansion by licensing out original agents as an important management strategy. Kissei ranks metabolism & endocrinology as one of its major R&D areas and is putting significant effort into the development of novel therapeutic agents. For more information on Kissei, please see the international website http://www.kissei.co.jp/.

Investor Contact:

BHV Pharma

James Green

919.789.1286

###

For the original version on PRWeb visit: http://www.prweb.com/releases/prweb2011/01/prweb4946674.htm


Source: prweb



comments powered by Disqus